Medical Therapies for Heart Failure in Hypoplastic Left Heart Syndrome

Significant surgical and medical advances over the past several decades have resulted in a growing number of infants and children surviving with hypoplastic left heart syndrome (HLHS) and other congenital heart defects associated with a single systemic right ventricle (RV). However, cardiac dysfunct...

Full description

Bibliographic Details
Main Authors: Angela N. Baybayon-Grandgeorge, Ashley E. Pietra, Shelley D. Miyamoto, Anastacia M. Garcia
Format: Article
Language:English
Published: MDPI AG 2022-05-01
Series:Journal of Cardiovascular Development and Disease
Subjects:
Online Access:https://www.mdpi.com/2308-3425/9/5/152
_version_ 1797498935357472768
author Angela N. Baybayon-Grandgeorge
Ashley E. Pietra
Shelley D. Miyamoto
Anastacia M. Garcia
author_facet Angela N. Baybayon-Grandgeorge
Ashley E. Pietra
Shelley D. Miyamoto
Anastacia M. Garcia
author_sort Angela N. Baybayon-Grandgeorge
collection DOAJ
description Significant surgical and medical advances over the past several decades have resulted in a growing number of infants and children surviving with hypoplastic left heart syndrome (HLHS) and other congenital heart defects associated with a single systemic right ventricle (RV). However, cardiac dysfunction and ultimately heart failure (HF) remain the most common cause of death and indication for transplantation in this population. Moreover, while early recognition and treatment of single ventricle-related complications are essential to improving outcomes, there are no proven therapeutic strategies for single systemic RV HF in the pediatric population. Importantly, prototypical adult HF therapies have been relatively ineffective in mitigating the need for cardiac transplantation in HLHS, likely due to several unique attributes of the failing HLHS myocardium. Here, we discuss the most commonly used medical therapies for the treatment of HF symptoms in HLHS and other single systemic RV patients. Additionally, we provide an overview of potential novel therapies for systemic ventricular failure in the HLHS and related populations based on fundamental science, pre-clinical, clinical, and observational studies in the current literature.
first_indexed 2024-03-10T03:40:24Z
format Article
id doaj.art-48a35e960bb54a1e83b4bc200a8fae38
institution Directory Open Access Journal
issn 2308-3425
language English
last_indexed 2024-03-10T03:40:24Z
publishDate 2022-05-01
publisher MDPI AG
record_format Article
series Journal of Cardiovascular Development and Disease
spelling doaj.art-48a35e960bb54a1e83b4bc200a8fae382023-11-23T11:32:53ZengMDPI AGJournal of Cardiovascular Development and Disease2308-34252022-05-019515210.3390/jcdd9050152Medical Therapies for Heart Failure in Hypoplastic Left Heart SyndromeAngela N. Baybayon-Grandgeorge0Ashley E. Pietra1Shelley D. Miyamoto2Anastacia M. Garcia3Department of Medicine, Division of Cardiology, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USADepartment of Pediatrics, Section of Cardiology, University of Colorado Anschutz Medical Campus, Children’s Hospital Colorado, Aurora, CO 80045, USADepartment of Pediatrics, Section of Cardiology, University of Colorado Anschutz Medical Campus, Children’s Hospital Colorado, Aurora, CO 80045, USADepartment of Pediatrics, Section of Cardiology, University of Colorado Anschutz Medical Campus, Children’s Hospital Colorado, Aurora, CO 80045, USASignificant surgical and medical advances over the past several decades have resulted in a growing number of infants and children surviving with hypoplastic left heart syndrome (HLHS) and other congenital heart defects associated with a single systemic right ventricle (RV). However, cardiac dysfunction and ultimately heart failure (HF) remain the most common cause of death and indication for transplantation in this population. Moreover, while early recognition and treatment of single ventricle-related complications are essential to improving outcomes, there are no proven therapeutic strategies for single systemic RV HF in the pediatric population. Importantly, prototypical adult HF therapies have been relatively ineffective in mitigating the need for cardiac transplantation in HLHS, likely due to several unique attributes of the failing HLHS myocardium. Here, we discuss the most commonly used medical therapies for the treatment of HF symptoms in HLHS and other single systemic RV patients. Additionally, we provide an overview of potential novel therapies for systemic ventricular failure in the HLHS and related populations based on fundamental science, pre-clinical, clinical, and observational studies in the current literature.https://www.mdpi.com/2308-3425/9/5/152congenital heart diseaseheart failurehypoplastic left heart syndrome
spellingShingle Angela N. Baybayon-Grandgeorge
Ashley E. Pietra
Shelley D. Miyamoto
Anastacia M. Garcia
Medical Therapies for Heart Failure in Hypoplastic Left Heart Syndrome
Journal of Cardiovascular Development and Disease
congenital heart disease
heart failure
hypoplastic left heart syndrome
title Medical Therapies for Heart Failure in Hypoplastic Left Heart Syndrome
title_full Medical Therapies for Heart Failure in Hypoplastic Left Heart Syndrome
title_fullStr Medical Therapies for Heart Failure in Hypoplastic Left Heart Syndrome
title_full_unstemmed Medical Therapies for Heart Failure in Hypoplastic Left Heart Syndrome
title_short Medical Therapies for Heart Failure in Hypoplastic Left Heart Syndrome
title_sort medical therapies for heart failure in hypoplastic left heart syndrome
topic congenital heart disease
heart failure
hypoplastic left heart syndrome
url https://www.mdpi.com/2308-3425/9/5/152
work_keys_str_mv AT angelanbaybayongrandgeorge medicaltherapiesforheartfailureinhypoplasticleftheartsyndrome
AT ashleyepietra medicaltherapiesforheartfailureinhypoplasticleftheartsyndrome
AT shelleydmiyamoto medicaltherapiesforheartfailureinhypoplasticleftheartsyndrome
AT anastaciamgarcia medicaltherapiesforheartfailureinhypoplasticleftheartsyndrome